Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Autoreactive helper T cells alleviate the need for intrinsic TLR signaling in autoreactive B cell activation
Josephine R. Giles, Adriana Turqueti Neves, Ann Marshak-Rothstein, Mark J. Shlomchik
Josephine R. Giles, Adriana Turqueti Neves, Ann Marshak-Rothstein, Mark J. Shlomchik
View: Text | PDF
Research Article Immunology

Autoreactive helper T cells alleviate the need for intrinsic TLR signaling in autoreactive B cell activation

  • Text
  • PDF
Abstract

T cells play a significant role in the pathogenesis of systemic autoimmune diseases, including systemic lupus erythematosus; however, there is relatively little information on the nature and specificity of autoreactive T cells. Identifying such cells has been technically difficult because they are likely to be rare and low affinity. Here, we report a method for identifying autoreactive T cell clones that recognize proteins contained in autoantibody immune complexes, providing direct evidence that functional autoreactive helper T cells exist in the periphery of normal mice. These T cells significantly enhanced autoreactive B cell proliferation and altered B cell differentiation in vivo. Most importantly, these autoreactive T cells were able to rescue many aspects of the TLR-deficient AM14 (anti-IgG2a rheumatoid factor) B cell response, suggesting that TLR requirements can be bypassed. This result has implications for the efficacy of TLR-targeted therapy in the treatment of ongoing disease.

Authors

Josephine R. Giles, Adriana Turqueti Neves, Ann Marshak-Rothstein, Mark J. Shlomchik

×

Figure 2

Primary IC-specific T cells respond to autoAb ICs and enhance AM14 B cell proliferation and differentiation in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Primary IC-specific T cells respond to autoAb ICs and enhance AM14 B cel...
AM14 B cells were cultured with T cells from DO11.10 BALB/c mice or from 13C2 Rg BALB/c mice in the presence of PL2-3 (1 μg/ml) or BWR4 (10 μg/ml). All cells were labeled with VPD450. AM14 B cells were identified with the anti-idiotype Ab, 4-44. The percentage of divided 4-44+ cells (A) was determined by flow cytometry on day 4. (B) Representative flow cytometry plots of AM14 B cells on day 3. Cells were first gated as live, surface, and intracellular 4-44+. 4-44+ IgM (C) and IgG2a (E) AFCs on day 4 were determined using ELIspot assay. The concentration of 4-44+ IgM (D) and IgG2a (F) in the culture supernatant on day 4 was measured by ELISA. (G) Representative flow cytometry plots of DO11.10 T cells (TCRVβ6–GFP–) and 13C2 T cells (TCRVβ6+GFP+) from the same culture on day 5. Cells are first gated as live, 4-44 CD3e+. The concentrations of IL-2 (H) and IFN-γ (I) in the culture supernatant on day 4 were measured by ELISA. Data are combined from 3 or 4 independent experiments. Data are represented as the percentage of maximum for each experiment; mean ± SEM. Statistics were calculated with 2-way ANOVA (A and C–F) or 1-way ANOVA (H and I); multiple testing was corrected with Holm-Sidak’s. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts